Boehringer Ingelheim recently announced the enrollment of the first patient in the Phase 3 clinical trial SENSCIS (Safety and Efficacy of Nintedanib in Systemic SClerosIS) evaluating the safety and efficacy of the company’s product nintedanib (OFEV) in patients with systemic sclerosis and interstitial lung disease.
Watch video above to learn more about OFEV.